Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 83

Results For "2022"

1420 News Found

Max Healthcare Institute Q1 FY23 consolidated PAT soars at Rs. 172.83 Cr
News | August 11, 2022

Max Healthcare Institute Q1 FY23 consolidated PAT soars at Rs. 172.83 Cr

The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.


Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr
News | August 11, 2022

Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr

The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.


Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr
News | August 10, 2022

Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr

The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.


Unichem Laboratories Q1 FY23 consolidated loss at Rs. 23.36 Cr
News | August 10, 2022

Unichem Laboratories Q1 FY23 consolidated loss at Rs. 23.36 Cr

The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022


Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director
People | August 10, 2022

Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director

He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years


Fortis Healthcare posts Q1 FY2023 consolidated PAT at Rs. 122.25 Cr
News | August 09, 2022

Fortis Healthcare posts Q1 FY2023 consolidated PAT at Rs. 122.25 Cr

The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.


Lyka Labs swings back to profit in Q1FY23
News | August 09, 2022

Lyka Labs swings back to profit in Q1FY23

The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.


Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
News | August 09, 2022

Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr

The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.


Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
News | August 09, 2022

Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher

Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.


Briefs: Zydus Lifesciences and Kimia Biosciences
News | August 09, 2022

Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.